Literature DB >> 17026620

Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes.

H Naseem1, J Boylan, D Speake, K Leask, A Shenton, F Lalloo, J Hill, D Trump, D G R Evans.   

Abstract

We assessed the association between breast cancer (BC) and colorectal cancer (CRC) from referral pattern to the Regional Genetics Service including molecular analysis. Hospital computer records and/or department referral books were used to identify cases referred to the Regional Genetic Service during a 16-year period (1990-2005 inclusive). All files were reviewed along with associated demographic data, risk assessments, referral details and results from mutation testing. Families were assessed for hereditary breast and colorectal cancer (HBCC) criteria, and all families with eligible individuals were tested for the 1100delC mutation in CHEK2. A total of 8,612 families were identified. One hundred and sixteen of 1,631 (7.5%) families with a primary referral for CRC fulfilled the criteria for HBCC, whereas only 68/6981 (1%) BC referrals fulfilled these criteria. Blood samples were obtained from 113 individuals from 83/184 families. Only 1/113 (1%) has screened positive for the CHEK2 mutation, whereas 14 (17%) families segregate BRCA1/2 mutations and at least 7 (8.5%) carry MLH1/MSH2 mutations. HBCC syndrome, if it exists as a separate entity, is not likely to be due to CHEK2 mutations. Many families are explicable by existing high-penetrance genes, and further work is necessary to elucidate whether the remainder is due to chance or as yet undiscovered genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17026620     DOI: 10.1111/j.1399-0004.2006.00698.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  Rare loss of function variants in candidate genes and risk of colorectal cancer.

Authors:  Elisabeth A Rosenthal; Brian H Shirts; Laura M Amendola; Martha Horike-Pyne; Peggy D Robertson; Fuki M Hisama; Robin L Bennett; Michael O Dorschner; Deborah A Nickerson; Ian B Stanaway; Rami Nassir; Kathy T Vickers; Christopher Li; William M Grady; Ulrike Peters; Gail P Jarvik
Journal:  Hum Genet       Date:  2018-09-28       Impact factor: 4.132

2.  ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients.

Authors:  Rolando A R Villacis; Francine B Abreu; Priscila M Miranda; Maria A C Domingues; Dirce M Carraro; Erika M M Santos; Victor P Andrade; Benedito M Rossi; Maria I Achatz; Silvia R Rogatto
Journal:  Tumour Biol       Date:  2015-10-01

3.  Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing.

Authors:  Hongsen Li; Liu Gong; Huanqing Cheng; Huina Wang; Xiaochen Zhang; Chuangzhou Rao; Zhangfa Song; Da Wang; Haizhou Lou; Feng Lou; Shanbo Cao; Hongming Pan; Yong Fang
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

4.  Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

Authors:  Renan Gomes; Pricila da Silva Spinola; Ayslan Castro Brant; Bruna Palma Matta; Caroline Macedo Nascimento; Silvia Maria de Aquino Paes; Cibele Rodrigues Bonvicino; Anna Claudia Evangelista Dos Santos; Miguel Angelo Martins Moreira
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

Review 5.  CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Authors:  Victoria Hale; Maren Weischer; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-11-06

6.  Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.

Authors:  Mala Pande; Aron Joon; Abenaa M Brewster; Wei V Chen; John L Hopper; Cathy Eng; Sanjay Shete; Graham Casey; Fredrick Schumacher; Yi Lin; Tabitha A Harrison; Emily White; Habibul Ahsan; Irene L Andrulis; Alice S Whittemore; Esther M John; Aung Ko Win; Enes Makalic; Daniel F Schmidt; Miroslaw K Kapuscinski; Heather M Ochs-Balcom; Steven Gallinger; Mark A Jenkins; Polly A Newcomb; Noralane M Lindor; Ulrike Peters; Christopher I Amos; Patrick M Lynch
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

Review 7.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

8.  Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.

Authors:  Patricia Ashton-Prolla; Juliana Giacomazzi; Aishameriane V Schmidt; Fernanda L Roth; Edenir I Palmero; Luciane Kalakun; Ernestina S Aguiar; Susana M Moreira; Erica Batassini; Vanessa Belo-Reyes; Lavinia Schuler-Faccini; Roberto Giugliani; Maira Caleffi; Suzi Alves Camey
Journal:  BMC Cancer       Date:  2009-08-14       Impact factor: 4.430

9.  Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas.

Authors:  Chioma J Madubata; Alireza Roshan-Ghias; Timothy Chu; Samuel Resnick; Junfei Zhao; Luis Arnes; Jiguang Wang; Raul Rabadan
Journal:  NPJ Genom Med       Date:  2017-10-03       Impact factor: 8.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.